Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Beneficial cilostazol therapeutic effects in mdx dystrophic skeletal muscle

Texto completo
Autor(es):
Hermes, Tulio de Almeida [1] ; Macedo, Aline Barbosa [1] ; Fogaca, Aline Reis [1] ; Rapucci Moraes, Luis Henrique [1] ; de Faria, Felipe Meira [1] ; Kido, Larissa Akemi [1] ; Alves Cagnon, Valeria Helena [1] ; Minatel, Elaine [1]
Número total de Autores: 8
Afiliação do(s) autor(es):
[1] State Univ Campinas UNICAMP, Inst Biol, Dept Struct & Funct Biol, BR-13083970 Campinas, SP - Brazil
Número total de Afiliações: 1
Tipo de documento: Artigo Científico
Fonte: Clinical and Experimental Pharmacology and Physiology; v. 43, n. 2, p. 259-267, FEB 2016.
Citações Web of Science: 5
Resumo

This study evaluated the possible protective effects of cilostazol against myonecrosis in dystrophic diaphragm muscle invivo, focusing on oxidative stress, the inflammatory response and angiogenesis. Young mdx mice, the experimental animal for Duchenne muscular dystrophy, received cilostazol for 14days. A second group of mdx mice and a control group of C57BL/10 mice received a saline solution. In the mdx mice, cilostazol treatment was associated with reduced loss of muscle strength (-34.4%), decreased myonecrosis, reduced creatine kinase levels (-63.3%) and muscle fibres stained for immunoglobulin G in dystrophic diaphragm muscle (-81.1%), and a reduced inflammatory response, with a decreased inflammatory area (-22%), macrophage infiltration (-44.9%) and nuclear factor-B (-24%) and tumour necrosis factor- (-48%) content in dystrophic diaphragm muscle. Furthermore, cilostazol decreased oxidative stress and attenuated reactive oxygen species production (-74%) and lipid peroxidation (-17%) in dystrophic diaphragm muscle, and promoted the up-regulation of angiogenesis, increasing the number of microvessels (15%). In conclusion, the present results show that cilostazol has beneficial effects in dystrophic muscle. More research into the potential of cilostazol as a novel therapeutic agent for the treatment of dystrophinopathies is required. (AU)

Processo FAPESP: 13/17299-9 - Efeito da associação de anti-inflamatório e antioxidante sobre células musculares distróficas
Beneficiário:Aline Reis Fogaça
Linha de fomento: Bolsas no Brasil - Iniciação Científica
Processo FAPESP: 13/01294-8 - A controvertida relação entre lesões prostáticas e inflamação: tratamentos com Celecoxibe e Goniotalamina em camundongos senis (FVB) e portadores do gene para o adenocarcinoma prostático (TRAMP)
Beneficiário:Larissa Akemi Kido de Barros
Linha de fomento: Bolsas no Brasil - Doutorado
Processo FAPESP: 11/02474-4 - Tratamento in vivo e in vitro com bloqueador de cálcio e antioxidante em camundongos mdx
Beneficiário:Elaine Minatel
Linha de fomento: Auxílio à Pesquisa - Regular